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Abstract
Background: There is a need to identify reliable markers for
malignant mesothelioma. Soluble mesothelin related peptides
(SMRP) and osteopontin (OPN) have gained interest in
recent years for this purpose.
Methods: SMRP (Fujirebio Diagnostics Inc.) and OPN
(R&D Inc.) ELISA methods were evaluated for multiple
parameters. Concentrations were measured in blood from
patients with mesothelioma, normal healthy volunteers, and
patients with other (non-mesothelioma) cancers. In silico
analysis was performed using the GeoProfiles database. At
the protein level, SMRP and OPN were measured in cell
culture supernatants, and values were compared in patients
pre- and post-extrapleural pneumonectomy.
Results: The SMRP assay demonstrates intra-assay CVs of
2.3% and 3% (at 4.6 nM and 13.7 nM, respectively), and
inter-assay CVs of 3.5% and 3.7% at the same concentra-
tions. The limit of detection (LOD) is 0.182 nM. The OPN
assay demonstrates intra-assay CVs of 5.8%, 4.1%, and 5.2%
(at 1.9, 5.1, and 11.1 ng/mL, respectively), and inter-assay
CVs of 8.5%, 8.4%, and 12.1% at the same concentrations.
The LOD is 0.032 ng/mL. Both SMRP and OPN in meso-
thelioma patients were significantly higher than in patients
with other (non-mesothelioma) cancer and in healthy vol-
unteers. The two markers do not appear to correlate with
each other and exhibit different tissue expression patterns.
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Protein concentrations of these markers are highest in dif-
ferent sets of cell lines. Finally, SMRP but not OPN concen-
trations were decreased in five of seven consecutive patients
after extrapleural pneumonectomy, compared to their respec-
tive pre-operative values.
Conclusions: These assays provide reliable and reproducible
quantitation of SMRP and OPN proteins. Both are increased
in mesothelioma patients compared to non-mesothelioma
controls. However, the two analytes do not correlate with
each other and show distinct expression profiles and protein
expression. Concentrations of SMRP but not OPN are
decreased in post-surgical samples. Our results further char-
acterize these markers, establish assay performance charac-
teristics, and lay the groundwork for further studies to
measure these markers in blood.
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Introduction
Diffuse malignant pleural mesothelioma is an uncommon
and lethal cancer for which there is currently no universally
accepted treatment standard (1–4). The incidence of malig-
nant mesothelioma is estimated at 2000–3000 cases annually
in the USA (5). In Western Europe alone, a quarter of a
million deaths are projected over the next 30 years (6). It is
important for thoracic physicians to be knowledgeable about
mesothelioma because they are often required to make a
diagnosis and recommend treatment.
Diagnosis of mesothelioma can be difficult. It presents
with a wide range of morphological characteristics on
histology, making it difficult to differentiate from other
malignancies (7). Similarities exist between epithelioid mes-
othelioma and metastatic adenocarcinoma. Immunohistoche-
mistry has been useful in differentiating mesothelioma from
adenocarcinoma. Many have found the distinction by iden-
tifying calretinin in mesothelioma and carcinoembryonic
antigen (CEA) in adenocarcinoma. Other difficulties exist in
differentiating sarcomatoid mesothelioma from synovial sar-
coma, desmoplastic mesothelioma from pleural fibrosis, and
well-differentiated mesothelioma from papillary hyperplasia.
No marker has 100% sensitivity or specificity for the diag-
nosis of mesothelioma, and commonly a panel of markers,
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such as CEA, tumor-associated glycoprotein 72 wB72.3x,
Leu-M1, vimentin, thrombomodulin, secretory component,
carcinoma antigen-125, and mucin is employed (8). Some-
times the distinction is still not possible and electron micro-
scopy is used to identify the numerous long microvilli pres-
ent in mesothelioma. A biomarker specific for the diagnosis
of mesothelioma would prove very useful for accurate
diagnosis.
Malignant pleural mesothelioma is also difficult to eval-
uate radiologically due to its propensity to infiltrate locally
into and along tissue planes. Computed tomography and
magnetic resonance imaging have been used to clinically
stage disease. Unfortunately, there are major discrepancies
when compared to surgical–pathological findings (9, 10).
There is evidence that the treatment of early stage disease
using extrapleural pneumonectomy or pleurectomy/decorti-
cation may improve survival (11–14). However, ;20%–
30% of patients undergo exploratory thoracotomy without
resection because of the unreliability of current radiological
modalities in predicting locally advanced disease (i.e., unre-
sectable disease) (2). Several studies have suggested that
FDG PET (position emission tomography) may be useful in
the pre-operative staging of this disease (15, 16). A better
method of determining extent of disease is necessary to
improve surgical outcome and minimize the number of
patients subjected to exploratory thoracotomy without sur-
gical resection. A biomarker that is a surrogate marker for
the extent of disease may help determine initial treatment,
response to treatment, and determine recurrence of disease
during routine follow-up.
Two markers, mesothelin and osteopontin (OPN), have
garnered interest in recent years for monitoring therapy or
detecting recurrence of mesothelioma. Mesothelin, encoded
by the MSLN gene, is a member of the megakaryocyte poten-
tiating factor (MPF) family and is produced specifically in
mesothelium cells. It is believed to play a role in cellular
adhesion. MSLN mRNA is translated into a preprotein form
which is post-translationally cleaved into two products, MPF
and mesothelin (17–19). Three mesothelin transcripts have
been reported in the literature: variant 1 encoding MPF
(NM_005823), variant 2 encoding mesothelin (NM_
013404), and variant 3 (AF180951) (20–24). Studies from
ovarian and pancreatic cancer cell lines and tissue support
the existence of variants 1 and 3 only, with variant 1 being
the predominant form (24). The mesothelin portion of this
protein is detectable using an ELISA method which
targets the soluble mesothelin related peptides (SMRP).
Because mesothelioma is a rare disease, this assay has been
FDA (Food and Drug Administration) approved for human-
itarian use and its intended application is to aid in the mon-
itoring of patients diagnosed with mesothelioma.
The second marker, OPN, is a glycoprotein that is abun-
dantly expressed by several cancers including lung, breast,
colorectal, gastric, ovarian, and melanoma (19). It is involved
in cell adhesion and has been shown to distinguish mesothe-
lioma patients from individuals that are exposed to asbestos
without malignancy (25). There are three isoforms of this
protein present in human cells: NM_001040058,
NM_000582, and NM_001040060 (26). OPN protein can be
detected in the circulation using antibodies that target this
protein.
The purpose of this study was to further characterize
mesothelin and OPN. We performed an analytical and clin-
ical validation of two ELISA based methods for these mark-
ers, established normal reference intervals for our patient
population, and characterized the protein concentrations in
blood samples from patients with different cancers. We also
assessed both molecules at the mRNA level in human tissues
and protein concentrations in cell line supernatants. Our
results help characterize further both mRNA and proteins for
these two markers, establish performance characteristics for
these assays, and lay the groundwork for further studies.
Materials and methods
SMRP ELISA immunoassay
SMRP ELISA – Mesomark (Fujirebio Diagnostics Inc., Malvern,
PA, USA) is a sandwich immunoassay used to quantitate SMRP in
human serum. There is a six-point standard curve (0–32 nM) and
the assay was performed per the manufacturer’s instructions. All
samples were measured in duplicate and the mean calculated. Brief-
ly, 10 mL of serum samples to be tested are diluted into 1 mL of
calibrator solution. 100 mL of calibrators, controls and diluted sam-
ples are dispensed into the appropriate well in the coated microtiter
plate and then incubated on a shaker for 60 min. The plate is decant-
ed and washed five times with 350 mL of wash buffer in each well.
Subsequently, 100 mL of conjugate (monoclonal antibody specific
for MSLN conjugated to horseradish peroxidase) is added and the
plate incubated for 60 min. The plate is then washed five times with
350 mL of wash buffer in each well. 100 mL of substrate solution
(tetramethylbenzidine) is added and the plate is incubated in the
dark for 15 min. 1% hydrochloric acid is added to stop the reaction
and the plate is read spectrophotometrically at 450 nm using a
BioTek ELx808 ultra microplate reader (BioTek Instruments Inc.,
Winooski, VT, USA).
Osteopontin immunoassay
The Quantikine OPN immunoassay (R&D Systems Inc., Minne-
apolis, MN, USA) is a 4.5-h solid-phase ELISA that employs a
sandwich immunoassay to quantitate human OPN in plasma (dilu-
tion required). The ELISA was performed per the manufacturer’s
instructions. All samples are measured in duplicate and the average
calculated. Briefly, a standard curve (4-parameter fit) is generated
by diluting a stock standard solution (200 ng/mL) to the following
concentrations: 20, 10, 5, 2.5, 1.25, 0.625, 0.312, and 0 ng/mL. One
hundred mL of diluent is added to 50 mL of standards, controls, or
samples into designated wells of the microtiter plate, and coated
with a monoclonal antibody specific to OPN. The plate is incubated
at room temperature for 2 h. It is then washed four times with wash
buffer and 200 mL of conjugate containing anti-OPN polyclonal
antibody-horseradish peroxidase conjugate is added to the wells.
After a 2-h, room temperature incubation, the plate is decanted and
washed four times with 400 mL of wash buffer. Finally, 200 mL of
substrate (tetramethylbenzidine) is added to the wells and the plate
is incubated in the dark for 30 min. The reaction is stopped by the
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addition of 50 mL of 2N sulfuric acid and read at 450 nm with l
correction at 530 nm.
Patient recruitment
Institutional Review Board approval was obtained at Memorial
Sloan-Kettering Cancer Center (MSK; New York, NY) for the col-
lection of serum and heparinized plasma from study patients. Con-
secutive clinic patients for whom eligibility criteria were met, i.e.,
mesothelioma diagnosis without previous treatment, were used in
this study. For these samples, the age range was 55–70 years, with
a median of 64 years. The majority of mesothelioma samples were
from patients in stage 2–3, including those that underwent extra-
pleural pneumonectomy. The remaining samples were from patients
in stage 4. Greater than 90% of samples had an epitheliod compo-
nent, i.e., comprised of pure epitheliod and also mixed histology
specimens. Less than 10% of the remaining specimens were from
patients with sarcomatoid mesothelioma.
Control samples were obtained from: 1) a pool of volunteer
healthy donors without evidence of disease; these donors had an
age range from 40 to 59 years, with a median of 54 years, 2) blood
samples from patients (ns10 each group) diagnosed with prostate,
breast, and ovarian cancer, most with late stage cancer, enrolled in
clinical protocols at MSK.
All patients signed informed consent for collection of blood and
tissue. A pilot cohort of seven consecutive patients who underwent
extrapleural pneumonectomy had mesothelin and OPN concentra-
tions measured before and after surgical resection at designated time
intervals, with comparisons performed on 1 week pre-surgical and
6 month post-surgical samples.
Sample collection and processing
Blood samples were centrifuged and serum/plasma separated within
30 min of collection. All samples were spun at 1500=g for 10 min
to separate cellular components. Serum or plasma were subsequent-
ly transferred to cryotubes and stored at y808C, until further
analysis.
Analytical parameters and statistical analysis
The limit of detection (LOD) was determined using 20 replicates of
a blank solution and calculated as follows: LODsmeanq2 SD.
Intra-assay precision was determined using 20 replicates of control
samples at the appropriate concentrations, and the mean, SD, and
CV (%) calculated. Inter-assay precision was calculated similarly,
using four daily runs.
Receiver operating characteristic (ROC) curves were created
using MedCalc (MedCalc Software, Mariakerke, Belgium) on a
cohort of 201 samples (140 mesotheliomaqnon-mesothelioma).
For comparison of SMRP and OPN between different sample
cohorts, a two-tailed heteroscedastic t-test was performed, with sig-
nificance set at ps0.05. For comparison of pre-surgical and post-
surgical samples, a paired, two-tailed Student’s t-test was performed,
and significance assessed using ps0.05.
Tissue survey mRNA
This tissue survey was performed in silico using the GEO profiles
database (accession number: GDS1096/204885_s_at/MSLN/Homo
sapiens for MSLN and GPL96/209875_s_at/Homo sapiens for
OPN). Results show expression profiling of 36 types of normal
tissue, with each RNA tissue sample pooled from several donors.
For additional experimental details, see reference (27). GAPDH
mRNA was used for normalization.
Cell culture samples
Three mesothelioma cell lines (VAMT, Meso37, and HMeso), three
lung cancer cell lines (A549, PC9, and H3255), and two other
immortalized cell lines (HeLa cervical adenocarcinoma cells and
HEK-293 human embryonal kidney cells) were used in this study.
For the lung cancer cell lines, A549 cells have activating mutation
in KRAS, PC9 cells have exon 19 deletion in epidermal growth
factor receptor (EGFR) and are sensitive to EGFR inhibitors, and
H3255 cells have the L858R mutation in EGFR and are sensitive
to EGFR inhibitors. All are NSCLC adenocarcinomas. Cell lines
were obtained courtesy of Molecular Diagnostics Service (Memorial
Hospital of MSK, New York, NY). HeLa cells were grown in
DMEM with 10% fetal calf serum (FCS) and penicillin (100 U/mL)
and streptomycin (100 mg/mL). The remaining cell lines were
grown in RPMI-1640 with 10% FCS and penicillin (100 U/mL) and
streptomycin (100 mg/mL). All cells were grown in a humidified
incubator at 378C and 5% CO2.
On day 0 of the study, 1=105 cells were plated into 100 mm=20
mm round cell culture dishes in triplicate. One mL of medium was
harvested from each dish at day 3. After harvesting, 1 mL of fresh
medium was returned to the dish to keep the total volume stable.
On day 4, all cells were trypsinized and counted. Cell counts ranged
from 2.5=105 cells per plate (H3255) to 9=106 cells per plate
(VAMT). All samples were sent for total protein quantitation imme-
diately after collection.
Results
Analytical validation
The SMRP assay demonstrated an intra-assay CV of 2.3%
at a mean of 4.6 nM, and 3% at a mean of 13.7 nM. The
inter-assay CV was 3.5% and 3.7% at these same concentra-
tions. The LOD was found to be 0.182 nM. For the OPN
assay, precision was assessed at three levels and the follow-
ing results were obtained: 5.8% at a mean of 1.9 ng/mL,
4.1% at a mean of 5.5 ng/mL, and 5.2% at a mean of
11.1 ng/mL. At these same levels, the inter-assay CV was
found to be 8.5%, 8.4%, and 12.5%, respectively. The LOD
for OPN was 0.032 ng/mL.
Reference interval assessment, ROC curves,
and correlation analysis
We measured SMRP concentrations in 51 healthy volunteers
and observed a range up to 0.82 nM. SMRP concentrations
in blood samples from patients with mesothelioma and non-
mesothelioma cancers are shown in Figure 1A. For OPN, we
observed a range of 7.5–67.5 ng/mL in normal individuals.
OPN concentrations in mesothelioma and non-mesothelioma
patients are shown in Figure 1B. To determine the utility of
these two markers in mesothelioma patients and normal vol-
unteer samples, we designed ROC curves for each, shown in
Figure 2A and B.
Interestingly, although each of the individual assays shows
excellent correlation when replicates for the same assay are
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Figure 1 SMRP and OPN concentrations in patients and controls.
(A) SMRP concentrations in mesothelioma (3.24"4.27, ns139),
normal (0.72"0.47, ns51), and non-mesothelioma (other cancer)
patients (0.63"1.12, ns30); (B) OPN concentrations in mesothe-
lioma (129"115, ns205), normal (41"19, ns51), and non-meso-
thelioma (other cancer) patients (43"35, ns30). p-Values are indi-
cated in inset for each of the comparisons.
Figure 2 ROC curve analysis.
Empirical ROC curve for separating mesothelioma patients vs. nor-
mal volunteers and patients with other cancers using (A) SMRP,
and (B) OPN. The AUC (95% CI) values are: 0.89 (0.83–0.92) for
SMRP and 0.68 (0.61–0.74) for OPN.
Figure 3 Correlation analysis: osteopontin vs. SMRP.
Correlation was performed using 135 samples for which both
mesothelin and osteopontin results were available.
compared, the concordance between mesothelin and OPN
proteins in these same specimens is poor (Figure 3).
Tissue survey mRNA
We interrogated the GeoProfiles database for expression lev-
els of mesothelin (MSLN, isoform 1) and OPN (isoform 1)
mRNAs in different human tissues. MSLN was expressed
highest in fetal lung, lung and trachea, with lower levels in
several other tissues (Figure 4A). We also investigated OPN
mRNA in the same sample set. OPN mRNA exhibited high-
est concentrations in kidney, with moderate expression in
corpus, fetal brain, pancreas, and placenta (Figure 4B).
Protein concentrations in cell lines
We also tested corresponding cell line supernatants from
eight representative cell lines. We found SMRP protein to be
highest in Meso37 and HeLa cell lines and OPN to be high-
est in A549 and PC9 cell lines (Figure 5).
Pre-operative vs. post-operative blood concentrations
from extrapleural pneumonectomy patients
We also obtained blood samples from seven consecutive
patients with mesothelioma who underwent extrapleural
pneumonectomy at Memorial Hospital. We measured blood
concentrations of SMRP and OPN from samples obtained
from these patients. The concentrations of SMRP decreased
in five of seven post-surgical patient samples (Figure 6). For
the remaining two patients, SMRP remained unchanged in
one patient and increased slightly in the other. OPN did not
show any consistent directional change in this small cohort
(data not shown).
Discussion
The treatment of malignant pleural mesothelioma is contro-
versial, but has evolved considerably during the past several
decades. However, many areas need further improvement:
easier and more accurate methods of pathological diagnosis,
improved methods of staging and of selecting patients for
surgery, assessment of response to chemotherapeutic and sur-
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Figure 4 Concentrations of (A) MSLN and (B) OPN mRNAs in
different human tissues.
(1) Adrenal gland, (2) amygdala, (3) bladder, (4) bone marrow, (5)
brain, (6) breast, (7) caudate nucleus, (8) cerebellum, (9) colon, (10)
corpus, (11) fetal brain, (12) fetal liver, (13) fetal lung, (14) heart,
(15) hippocampus, (16) kidney, (17) liver, (18) lung, (19) ovary,
(20) pancreas, (21) pituitary gland, (22) placenta, (23) prostate, (24)
smooth muscle, (25) salivary gland, (26) skin, (27) small intestine,
(28) spinal cord, (29) spleen, (30) stomach, (31) testis, (32) thala-
mus, (33) thymus, (34) thyroid, (35) trachea, (36) uterus. Note that
mRNA levels are normalized to GAPDH.
Figure 5 Concentrations of SMRP and osteopontin protein in cell
line supernatants.
Figure 6 Comparison of SMRP concentrations in pre- and post-
specimens from 7 extrapleural pneumonectomy (EPP) surgery
patients.
gical treatment, and assessment of disease recurrence in rou-
tine follow-up (28–33). Non-invasively obtained biomarkers
specific to mesothelioma would improve care for all aspects
of disease assessment and treatment (18, 20). In this study,
we further characterized two markers, mesothelin and OPN,
at the mRNA and protein levels, and defined the perform-
ance characteristics for ELISA methods for quantitative anal-
ysis in cell lines and blood.
Mesothelin is a differentiation antigen previously identi-
fied in pleura, peritoneum, and pericaridium (34). In humans,
it is encoded by the MSLN gene which produces a protein
of 71 kDa. This preprotein is the target of certain furin-like
proteases that cleave the molecule into two fragments. A 31-
kDa amino terminal fragment called MPF is released into the
circulation, and a 40-kDa product, mesothelin, remains
membrane bound. Three molecular variants of mesothelin
have been reported in the literature (accession numbers
NM_005823.4, NM_013404.3, and AF180951), but only the
existence of variants 1 and 3 has been demonstrated in
ovarian and pancreatic cell lines and ovarian cancer tissue
(17, 34).
OPN is a glycoprotein that is overexpressed in many
human cancers including lung, breast, colorectal, gastric,
ovarian, and melanoma (19). One important role for OPN
lies in its ability to distinguish mesothelioma from asbestos
exposure without malignancy (19, 25). There are three genes
encoding isoforms a, b, and c of OPN (accession numbers
NM_001040058.1, NM_000582.2, and NM_001040060.1)
(26).
We validated assays for both SMRP and OPN, and used
them for quantitation of the concentrations of their respective
proteins in blood samples from patients with and without
mesothelioma (Figure 1). Performance characteristics includ-
ing intra-assay and inter-assay precision, LOD, reference
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interval assessment and comparison of concentrations of both
proteins in mesothelioma and non-mesothelioma patients
were determined. Our data suggest satisfactory performance
of these assays in measurement of their respective analytes.
They also provide baseline measurements and lay the ground-
work for additional studies using blood samples from
patients with and without mesothelioma and those under-
going treatment. Our results from LOD and precision studies
are in close agreement with those of Beyer et al. (35). In
addition, our reference interval data are narrower but consis-
tent with the broader range established in this former study.
SMRP and OPN values do not correlate with each other
(Figure 3). This suggests that at a functional level, the pro-
teins are not redundant and thus likely to be involved in
distinct pathways. This possibility is further reinforced by
the different expression patterns of these two biomarkers. An
in silico analysis of MSLN and OPN mRNAs in 36 human
tissues was performed using GeoProfiles (http://www.ncbi.
nlm.nih.gov/sites/entrez); see Figure 4. MSLN, the gene
which encodes mesothelin, and whose protein product is
detected by the SMRP assay, shows highest concentrations
in fetal lung, lung, and trachea, with lower concentrations in
several other tissues. In contrast, the OPN gene is expressed
in highest amounts in kidney, with moderate levels in corpus,
fetal brain, pancreas and placenta. The distinct expression
pattern of these two molecules suggests different functions.
We measured the concentrations of both SMRP and OPN
proteins in eight representative cancer cell lines. For SMRP,
we observed highest protein concentrations in the superna-
tants of Meso37 and HeLa, with values below detection for
the rest of the cell lines. It is remarkable that only one of
the mesothelioma cell lines (Meso37) showed measurable
concentrations of this marker. In reviewing microarray
expression data obtained from analysis of these three cell
lines, we noted that the Meso37 cell line expresses mesothe-
lin mRNA at two orders of magnitude higher than VAMT
and HMeso cell lines (data not shown). Thus, it is possible,
and consistent with our ELISA results, that Meso37 produces
mesothelin protein at concentrations that fall within the
dynamic range of our assay and that the other cell lines
which contain 100= less mesothelin mRNA produce values
below detectable limits when measured with our assay.
For OPN, we observed highest concentrations of this pro-
tein in A549 and PC9 cell lines, with concentrations below
the detection limit for the remaining cell lines. Both A549
and PC9 are derived from lung cancer patients. It is inter-
esting that H3255, which is also a lung cancer derived cell
line, does not show measurable concentrations of OPN, par-
ticularly since both PC9 and H3255 are sensitive to EGFR
inhibitors. At the molecular level, PC9 cells contain EGFR
with exon 19 deletion, and H3255 cells contain EGFR with
L858R mutation. It is conceivable that such a difference
could activate different downstream effector proteins with
only PC9 cells activating a signal transduction pathway that
results in mesothelin protein production and/or secretion.
Interestingly, A549 cells which contain an activating KRAS
mutation, activates downstream signaling resulting in meso-
thelin secretion similar to PC9 cells.
To assess reference intervals, we measured the concentra-
tions of SMRP and OPN in a cohort comprised of normal
healthy volunteers, mesothelioma and non-mesothelioma
(i.e., other cancer) patients. In 51 normal healthy volunteers,
we observed a range of values up to 0.82 nM. This measured
range is narrower, but falls within the reference interval stat-
ed in the product insert and based on the study by Beyer
et al., who calculated the 99th percentile of the reference
group to be 1.5 nM (35). This discrepancy can be reconciled
by the size of our reference group (ns51) which is much
smaller than that of theirs (ns409). When we measured
samples from mesothelioma patients, they showed a broad
range of results with maximum at 26 nM. Patients with pros-
tate, breast, and ovarian cancer exhibited values up to 5 nM.
OPN concentrations were measured in the same cohort,
and are shown in Figure 1B. Similar to SMRP, highest values
were observed in mesothelioma patients (maximum of
525 ng/mL), lower concentrations in patients with other can-
cer (maximum of 200 ng/mL), and values levels in normal
healthy volunteers (maximum of 70 ng/mL). Our observed
values are somewhat lower than those suggested by the man-
ufacturer (53–195 ng/mL), but this difference may be rec-
onciled by the small cohort of 51 patients analyzed in our
study, or the possibility that our patient population is differ-
ent from that previously tested.
Finally, we analyzed SMRP and OPN concentrations in a
small group of seven consecutive patients undergoing extra-
pleural pneumonectomy. We observed that SMRP, but not
OPN, showed a decrement in five of seven post-surgical
samples as compared to paired pre-surgical specimens.
Although this result did not achieve statistical significance
(ps0.07), it would be of great interest to assess concentra-
tions of this marker at different time points and/or in a larger
cohort of paired samples.
In conclusion, our data establish the reliability and repro-
ducibility of two assays to quantitate SMRP and OPN pro-
teins. We assessed reference intervals for both markers and
show that the two do not correlate well in our sample set.
Tissue expression surveys at the mRNA level show distinct
profiles, as do the concentrations of the corresponding pro-
teins in cell line supernatants. Finally, concentrations of
SMRP but not OPN, decrease in post-surgical samples after
extrapleural pneumonectomy. This is a promising prelimi-
nary result and warrants further investigation in a larger
cohort.
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